Facebook Twitter Linkedin Pinterest Youtube Instagram

Bridging the Gap Between Participants and Clinical Trials

The Diabetes and Renal Research Unit. The Launceston General Hospital

Condition(s): Metabolic and Endocrine

ADDRESS: The Launceston General Hospital,Level 5, 274-280 Charles St, Launceston, TAS 7250

PHONE: 03 6777 6960

Facebook Twitter Youtube Linkedin Instagram

Name: Ingrid Meyer
Role:  Administrator
Phone: 03 6777 6960
Email: lgh.field.study@ths.tas.gov.au

Name: Sharon Smith
Role: Study Nurse
Phone: 03 6777 6927
Email: lgh.field.study@ths.tas.gov.au

Name: Jennifer Shepherd
Role: Study Coordinator
Phone: 03 6777 6927
Email: lgh.field.study@ths.tas.gov.au




Monday:

Tuesday:

Wednesday:

Thursday:

Friday:

Saturday:

Sunday:

Sites Contact Form

The Launceston General Hospital Diabetes and Renal Research Unit, three Principal Investigators and one 4 Investigator. We have two Nurse Study Coordinators and one Administrative Study Coordinator.
We are situated in the Clifford Craig Research Trust of The Launceston General Hospital with several other research units. All endocrinologists, nephrologists and general physicians who work at this public hospital also have private rooms close by, and service a large area of North, North West, East and Central Tasmania, so we recruit patients from both the private and public sector.
We have access to all the facilities you would expect of a public teaching hospital, including, Pharmacy, Radiology, Renal Unit, and a Pathology who process and ship all our trials samples. They have all the qualifications and certifications that are required by sponsors for clinical trials.
All Site staff maintain their current GCP training, and have in excess of ten years experience in clinical trials in the diabetes and renal area.
The Tasmanian Health and Medical Human Research Ethics Committee review all our Clinical Trials. Non-substantial amendments are often reviewed by the Ethics Executive Officer in which case the approval process takes only one to two weeks. Substantial amendments go to the full committee meetings which occur monthly except for December, in which case the review process can take up to 5 weeks. If amendments have prior approval from an approved Ethics Committee, the process is considerably quicker. The fact that our site has an administrative coordinator means that all administrative processes, including data entry and review are attended to more promptly than most sites.
The site has never been audited by a regulatory authority.

Therapeutic Areas: Diabetes and Nephrology.

COVID INFO

CURRENT CLINICAL TRIALS

No active clinical trials

JOBS (CURRENT OPEN POSITIONS)

No current jobs

SITE EXPERIENCE

Protocol title: A Prospective, Immunogenicity Surveillance Registry (PRIMS) to Estimate the Incidence of Erythropoietin Antibody-Mediated Pure Red Cell Aplasia Among Subjects With Chronic Renal Failure and Subcutaneous Exposure to Recombinant Erythropoietin Products
Registry: ClinicalTrials.gov
Registry #: NCT00391287
Link to registry: See Registry

Protocol title: A Multi-center, Longitudinal, Observational Study of Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Establish the Rate, Characteristics, and Determinants of Disease Progression
Registry: ClinicalTrials.gov
Registry #: NCT01430494
Link to registry: See Registry

Protocol title: Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Tria
Registry: ClinicalTrials.gov
Registry #: NCT00125593
Link to registry: See Registry

Protocol title: Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcome
Registry: Australian New Zealand Clinical Trials Registry (ANZCTR)
Registry #: NCT01687998
Link to registry: See Registry

Protocol title: A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/Day, Split Dose) in Subjects With Autosomal Dominant Polycystic Kidney Diseas
Registry: Australian New Zealand Clinical Trials Registry (ANZCTR)
Registry #: NCT02251275
Link to registry: See Registry

Protocol title: A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/Day, Split-dose) in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
Registry: Australian New Zealand Clinical Trials Registry (ANZCTR)
Registry #: NCT02160145
Link to registry: See Registry

Protocol title: A Phase 3, Multicenter, Randomized, Open-label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients
Registry: Australian New Zealand Clinical Trials Registry (ANZCTR)
Registry #: NCT02174731
Link to registry: See Registry

Protocol title: FGCL-4592: A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis
Registry: Australian New Zealand Clinical Trials Registry (ANZCTR)
Registry #: NCT01750190
Link to registry: See Registry

Protocol title: A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)
Registry: Australian New Zealand Clinical Trials Registry (ANZCTR)
Registry #: NCT00773513
Link to registry: See Registry

Protocol title: SONAR M11-352 A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy.
Registry: Australian New Zealand Clinical Trials Registry (ANZCTR)
Registry #: NCT01858532
Link to registry: See Registry

Protocol title: 28431574DIA4003
Registry: Australian New Zealand Clinical Trials Registry (ANZCTR)
Registry #: NCT01989754
Link to registry: See Registry

Protocol title: A randomized, Multicentre, Double-Blid, Parallel, PLacebo-Controlled Study of the effects of JNJ-28431754 on Cardiovascular Outcomes in Adult subjects With Type 2 Diabetes Mellitus
Registry: Australian New Zealand Clinical Trials Registry (ANZCTR)
Registry #: NCT01032629
Link to registry: See Registry

Want access to more Site details?

Sponsors and CROs looking to choose Sites for their next clinical trial are encouraged to sign up to AustralianClinicalTrials.com. In doing so, you will get free access to any and all Site Selection Packages, ready for you to download. Curated by Sites themselves, all the information you need to know for selection is presented in an easy to read format, saving you time and money. Create an account, and become a part of the fastest growing clinical trials community today!